Format

Send to

Choose Destination
Curr Psychiatry Rep. 2010 Oct;12(5):366-73. doi: 10.1007/s11920-010-0136-4.

Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.

Author information

1
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, 27710, USA. cinnamon.bidwell@duke.edu

Abstract

Pharmacologic management of attention-deficit/hyperactivity disorder (ADHD) has expanded beyond stimulant medications to include alpha-2 adrenergic agonists. These agents exert their actions through presynaptic stimulation and likely involve facilitation of dopamine and noradrenaline neurotransmission, both of which are thought to play critical roles in the pathophysiology of ADHD. Furthermore, frontostriatal dysfunction giving rise to neuropsychological weaknesses has been well-established in patients with ADHD and may explain how alpha-2 agents exert their beneficial effects. In the following review, we consider relevant neurobiological underpinnings of ADHD with respect to why alpha-2 agents may be effective in treating this condition. We also review new formulations of alpha-2 agonists, emerging data on their use in ADHD, and implications for clinical practice. Integrating knowledge of pathophysiologic mechanisms and mechanisms of drug action may inform our medication choices and facilitate treatment of ADHD and related disorders.

PMID:
20652773
PMCID:
PMC3676929
DOI:
10.1007/s11920-010-0136-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center